$GOSS
Gossamer Bio, Inc.

2021 Q4 Form 10-Q Financial Statement

#000172811721000104 Filed on November 08, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.71M $12.46M $11.26M
YoY Change -32.53% 8.81% -3.4%
% of Gross Profit
Research & Development $40.93M $43.19M $44.32M
YoY Change 5.2% 3.21% 14.56%
% of Gross Profit
Depreciation & Amortization $448.0K $450.0K $422.0K
YoY Change 21.08% 25.0% 20.57%
% of Gross Profit
Operating Expenses $51.65M $55.66M $55.60M
YoY Change -5.74% 3.91% -14.91%
Operating Profit -$55.66M -$55.60M
YoY Change 3.91% -14.91%
Interest Expense -$4.701M $4.889M $4.834M
YoY Change 34.31% 3.69% 94.06%
% of Operating Profit
Other Income/Expense, Net $78.00K -$4.583M -$4.236M
YoY Change -107.65% 8.01% 176.68%
Pretax Income -$56.28M -$60.25M -$59.83M
YoY Change -12.87% 4.22% -10.52%
Income Tax
% Of Pretax Income
Net Earnings -$56.28M -$60.25M -$59.83M
YoY Change -12.87% 4.21% -10.52%
Net Earnings / Revenue
Basic Earnings Per Share -$0.80 -$0.80
Diluted Earnings Per Share -$744.5K -$0.80 -$0.80
COMMON SHARES
Basic Shares Outstanding 76.46M shares 75.00M shares 74.67M shares
Diluted Shares Outstanding 75.00M shares 74.67M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $325.2M $366.0M $405.9M
YoY Change -36.56% -34.1% -32.39%
Cash & Equivalents $183.4M $213.5M $342.5M
Short-Term Investments $141.8M $152.5M $63.47M
Other Short-Term Assets $6.562M $7.972M $11.07M
YoY Change -32.35% -26.19% 38.35%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $331.8M $374.0M $417.0M
YoY Change -36.48% -33.95% -31.46%
LONG-TERM ASSETS
Property, Plant & Equipment $5.320M $5.621M $5.632M
YoY Change -3.87% -1.68% -2.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.080M $1.114M $1.070M
YoY Change 5.16% 29.38% 78.33%
Total Long-Term Assets $11.88M $13.05M $15.52M
YoY Change -30.59% -27.41% -7.05%
TOTAL ASSETS
Total Short-Term Assets $331.8M $374.0M $417.0M
Total Long-Term Assets $11.88M $13.05M $15.52M
Total Assets $343.7M $387.0M $432.5M
YoY Change -36.29% -33.75% -30.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.244M $1.185M $895.0K
YoY Change -56.79% 36.99% 347.5%
Accrued Expenses $20.41M $20.91M $15.88M
YoY Change -1.45% 7.19% -41.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $39.86M $35.90M $29.98M
YoY Change 3.13% 10.09% 9.03%
LONG-TERM LIABILITIES
Long-Term Debt $29.08M $28.99M $28.91M
YoY Change 1.17% 1.14% 0.94%
Other Long-Term Liabilities $3.218M $3.964M $6.165M
YoY Change -58.21% -53.91% -21.96%
Total Long-Term Liabilities $29.08M $28.99M $28.91M
YoY Change 1.17% 1.14% 0.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $39.86M $35.90M $29.98M
Total Long-Term Liabilities $29.08M $28.99M $28.91M
Total Liabilities $222.2M $217.2M $211.8M
YoY Change 1.57% 2.43% 3.45%
SHAREHOLDERS EQUITY
Retained Earnings -$811.5M -$755.3M -$695.0M
YoY Change 40.53% 47.26%
Common Stock $933.0M $924.9M $915.4M
YoY Change 3.94% 4.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $121.5M $169.8M $220.7M
YoY Change
Total Liabilities & Shareholders Equity $343.7M $387.0M $432.5M
YoY Change -36.29% -33.75% -30.81%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income -$56.28M -$60.25M -$59.83M
YoY Change -12.87% 4.21% -10.52%
Depreciation, Depletion And Amortization $448.0K $450.0K $422.0K
YoY Change 21.08% 25.0% 20.57%
Cash From Operating Activities -$40.51M -$42.04M -$47.45M
YoY Change 10.26% -6.44% 11.93%
INVESTING ACTIVITIES
Capital Expenditures -$83.00K -$523.0K -$140.0K
YoY Change -66.8% 74.33% -68.18%
Acquisitions
YoY Change
Other Investing Activities $10.53M -$89.24M -$49.94M
YoY Change -82.84% -540.47% -146.81%
Cash From Investing Activities $10.44M -$89.76M -$50.08M
YoY Change -82.91% -549.71% -147.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 371.0K 1.913M 275.0K
YoY Change 48.4% 114.94% -99.91%
NET CHANGE
Cash From Operating Activities -40.51M -42.04M -47.45M
Cash From Investing Activities 10.44M -89.76M -50.08M
Cash From Financing Activities 371.0K 1.913M 275.0K
Net Change In Cash -29.69M -129.9M -97.25M
YoY Change -220.66% 439.39% -125.96%
FREE CASH FLOW
Cash From Operating Activities -$40.51M -$42.04M -$47.45M
Capital Expenditures -$83.00K -$523.0K -$140.0K
Free Cash Flow -$40.43M -$41.51M -$47.31M
YoY Change 10.79% -6.99% 12.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001728117
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2021Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38796
dei Entity Registrant Name
EntityRegistrantName
GOSSAMER BIO, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-5461709
dei Entity Address Address Line1
EntityAddressAddressLine1
3013 Science Park Road
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
684-1300
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
GOSS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
76463531 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
213474000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
486055000 USD
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
152546000 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
26573000 USD
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
64000 USD
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
565000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7908000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9129000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
373992000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
522322000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5621000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5534000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6311000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10550000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1114000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1027000 USD
CY2021Q3 us-gaap Assets
Assets
387038000 USD
CY2020Q4 us-gaap Assets
Assets
539433000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1185000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7508000 USD
CY2021Q3 goss Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
13806000 USD
CY2020Q4 goss Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
10431000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20905000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20711000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
35896000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38650000 USD
CY2021Q3 goss Long Term Convertible Senior Notes
LongTermConvertibleSeniorNotes
148378000 USD
CY2020Q4 goss Long Term Convertible Senior Notes
LongTermConvertibleSeniorNotes
143642000 USD
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
28991000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
28744000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3964000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7713000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
217229000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
218749000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
70000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
70000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
700000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
700000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76225279 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75300074 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75524254 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73874904 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
8000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
8000 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
924914000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
897607000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-755250000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-577530000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
137000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
599000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
169809000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
320684000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
387038000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
539433000 USD
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
43190000 USD
CY2020Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
41846000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
129335000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
121944000 USD
CY2021Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
15000 USD
CY2020Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
275000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
60000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
18080000 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12459000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11448000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35068000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33851000 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
55664000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
53569000 USD
us-gaap Operating Expenses
OperatingExpenses
164463000 USD
us-gaap Operating Expenses
OperatingExpenses
173875000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-55664000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-53569000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-164463000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-173875000 USD
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
191000 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
580000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
525000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
3076000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
4889000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
4715000 USD
us-gaap Interest Expense
InterestExpense
14503000 USD
us-gaap Interest Expense
InterestExpense
7913000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
115000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-108000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
721000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-44000 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4583000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4243000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13257000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4881000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-60247000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-57812000 USD
us-gaap Net Income Loss
NetIncomeLoss
-177720000 USD
us-gaap Net Income Loss
NetIncomeLoss
-178756000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-64000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
68000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-274000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
59000 USD
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-73000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-293000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-188000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
25000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-137000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-225000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-462000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
84000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60384000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58037000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-178182000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-178672000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.67
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75001510 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75001510 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72245897 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72245897 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74592632 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74592632 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66931512 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66931512 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
320684000 USD
CY2021Q1 goss Stock Issued During Period Value Vesting Of Restricted Stock
StockIssuedDuringPeriodValueVestingOfRestrictedStock
0 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8708000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
759000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-57641000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-441000 USD
CY2021Q1 goss Stock Issued During Period Value Vesting Of Restricted Stock
StockIssuedDuringPeriodValueVestingOfRestrictedStock
0 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
272084000 USD
CY2021Q2 goss Stock Issued During Period Value Vesting Of Restricted Stock
StockIssuedDuringPeriodValueVestingOfRestrictedStock
0 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
271000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8054000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-59832000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
116000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
220693000 USD
CY2021Q3 goss Stock Issued During Period Value Vesting Of Restricted Stock
StockIssuedDuringPeriodValueVestingOfRestrictedStock
0 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1357000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7587000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
556000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-60247000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-137000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
169809000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
352485000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8244000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
556000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-54074000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-763000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
306463000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
117094000 USD
CY2020Q2 goss Equity Component Of Convertible Note Issuance
EquityComponentOfConvertibleNoteIssuance
53635000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
109000 USD
CY2021Q2 goss Stock Issued During Period Value Vesting Of Restricted Stock
StockIssuedDuringPeriodValueVestingOfRestrictedStock
0 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
139000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8900000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-66870000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1072000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
420324000 USD
CY2021Q3 goss Stock Issued During Period Value Vesting Of Restricted Stock
StockIssuedDuringPeriodValueVestingOfRestrictedStock
0 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
131000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8923000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
744000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
16000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-57812000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-225000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
372101000 USD
us-gaap Profit Loss
ProfitLoss
-177720000 USD
us-gaap Profit Loss
ProfitLoss
-178756000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1292000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1044000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
24349000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
26067000 USD
goss In Process Research And Development Expenses
InProcessResearchAndDevelopmentExpenses
60000 USD
goss In Process Research And Development Expenses
InProcessResearchAndDevelopmentExpenses
18080000 USD
goss Amortization Of Operating Lease Right Of Use Assets
AmortizationOfOperatingLeaseRightOfUseAssets
2593000 USD
goss Amortization Of Operating Lease Right Of Use Assets
AmortizationOfOperatingLeaseRightOfUseAssets
2015000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4983000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2294000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-186000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-24000 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
256000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-84000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1221000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3340000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
87000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-698000 USD
goss Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
2706000 USD
goss Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
1294000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6808000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4715000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2768000 USD
goss Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
3375000 USD
goss Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-7019000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3918000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1959000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-148381000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-139624000 USD
goss Payments For Proceeds From Research And Development Asset Acquisitions
PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions
60000 USD
goss Payments For Proceeds From Research And Development Asset Acquisitions
PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions
18080000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
143897000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
108969000 USD
goss Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
17550000 USD
goss Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
199029000 USD
goss Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
0 USD
goss Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
83515000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1463000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1253000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-127870000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
154242000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
117110000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
193596000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1315000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1300000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1643000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
285000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2958000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
312291000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
211000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-42000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-273082000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
326867000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
486620000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135089000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
213538000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
461956000 USD
us-gaap Interest Paid Net
InterestPaidNet
7055000 USD
us-gaap Interest Paid Net
InterestPaidNet
1911000 USD
goss Right Of Use Assets Obtained In Exchange For Lease Liabilities
RightOfUseAssetsObtainedInExchangeForLeaseLiabilities
0 USD
goss Right Of Use Assets Obtained In Exchange For Lease Liabilities
RightOfUseAssetsObtainedInExchangeForLeaseLiabilities
3106000 USD
goss Derecognition Of Operating Lease Obligation And Right Of Use Asset
DerecognitionOfOperatingLeaseObligationAndRightOfUseAsset
1650000 USD
goss Derecognition Of Operating Lease Obligation And Right Of Use Asset
DerecognitionOfOperatingLeaseObligationAndRightOfUseAsset
0 USD
goss Noncash Investing And Financing Activities Change In Unrealized Gain On Marketable Securities Net Of Tax
NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax
188000 USD
goss Noncash Investing And Financing Activities Change In Unrealized Gain On Marketable Securities Net Of Tax
NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax
25000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
83000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-755300000 USD
goss Funds Raised Through Preferred Equity Financing Convertible Note Financings And Completed Initial Public Offering
FundsRaisedThroughPreferredEquityFinancingConvertibleNoteFinancingsAndCompletedInitialPublicOffering
942000000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the allocation of the 2027 Notes into liability and equity components and accrued research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9517000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8157000 USD
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3896000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2623000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5621000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5534000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9591000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12194000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3030000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3633000 USD
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1475000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2823000 USD
CY2021Q3 us-gaap Interest Payable Current
InterestPayableCurrent
3558000 USD
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1094000 USD
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
806000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
742000 USD
CY2021Q3 us-gaap Litigation Reserve Current
LitigationReserveCurrent
2400000 USD
CY2020Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
0 USD
CY2021Q3 goss Accrued In Process Research And Development
AccruedInProcessResearchAndDevelopment
45000 USD
CY2020Q4 goss Accrued In Process Research And Development
AccruedInProcessResearchAndDevelopment
225000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20905000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20711000 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2503356 shares
CY2021Q3 us-gaap Fair Value Equity Level2 To Level1 Transfers Amount
FairValueEquityLevel2ToLevel1TransfersAmount
0 USD
CY2020Q4 us-gaap Fair Value Equity Level2 To Level1 Transfers Amount
FairValueEquityLevel2ToLevel1TransfersAmount
0 USD
CY2021Q3 us-gaap Fair Value Equity Level1 To Level2 Transfers Amount
FairValueEquityLevel1ToLevel2TransfersAmount
0 USD
CY2020Q4 us-gaap Fair Value Equity Level1 To Level2 Transfers Amount
FairValueEquityLevel1ToLevel2TransfersAmount
0 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
152557000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
16000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
27000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
152546000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
144888000 USD
CY2021Q3 goss Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
7658000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
152546000 USD
CY2018Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
20000000 USD
CY2021Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
15000 USD
CY2020Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
275000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
60000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
18080000 USD
goss Common Stock Voting Rights Number Of Votes Per Share
CommonStockVotingRightsNumberOfVotesPerShare
1 vote
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9433963 shares
CY2020Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
13.25
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
117100000 USD
CY2021Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
925208 shares
CY2020Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
1649348 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9401082 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.42
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10182000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2923501 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.67
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
280895 shares
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7587000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
14.01
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9540332 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.33
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
22958000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
4521056 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
12.74
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
12414000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
8.41
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8923000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24349000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26067000 USD
CY2019Q4 goss Option To Extend Contract Exercise Period
OptionToExtendContractExercisePeriod
P9M
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.07
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1008000 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1007000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
3084000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
2577000 USD
CY2021Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
13000 USD
CY2020Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
16000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
34000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
54000 USD
CY2021Q3 us-gaap Lease Cost
LeaseCost
1021000 USD
CY2020Q3 us-gaap Lease Cost
LeaseCost
1023000 USD
us-gaap Lease Cost
LeaseCost
3118000 USD
us-gaap Lease Cost
LeaseCost
2631000 USD
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1000000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
3200000 USD
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1000000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
2600000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
985000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3220000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1694000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1746000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7645000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
651000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6994000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3030000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3964000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6994000 USD
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
3300000 USD
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1000000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
1900000 USD

Files In Submission

Name View Source Status
0001728117-21-000104-index-headers.html Edgar Link pending
0001728117-21-000104-index.html Edgar Link pending
0001728117-21-000104.txt Edgar Link pending
0001728117-21-000104-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
goss-20210930.htm Edgar Link pending
goss-20210930.xsd Edgar Link pending
goss-20210930x10qxexx311.htm Edgar Link pending
goss-20210930x10qxexx312.htm Edgar Link pending
goss-20210930x10qxexx321.htm Edgar Link pending
goss-20210930x10qxexx322.htm Edgar Link pending
goss-20210930_cal.xml Edgar Link unprocessable
goss-20210930_def.xml Edgar Link unprocessable
goss-20210930_htm.xml Edgar Link completed
goss-20210930_lab.xml Edgar Link unprocessable
goss-20210930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending